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GUIDELINE
Prevention and management of physical 
health conditions in adults with severe mental 
disorders: WHO recommendations
Petra C. Gronholm2*† , Neerja Chowdhary1†, Corrado Barbui3, Jayati Das‑Munshi4, Kavitha Kolappa1,5, 
Graham Thornicroft2, Maya Semrau2,6† and Tarun Dua1†
Abstract 
Background: People with severe mental disorders (SMD) experience premature mortality mostly from preventable 
physical causes. The World Health Organization (WHO) have recently produced guidelines on the prevention and 
management of physical health conditions in SMD. This paper presents the evidence which led to the recommenda‑
tions presented in the guidelines.
Methods: The work followed the methodological principles for WHO guideline development. Systematic reviews in rela‑
tion to the treatment of seven key priority physical health conditions and associated risk factors in persons with SMD were 
systematically sourced. The quality of this evidence was assessed, and compiled into evidence profiles. Existing guidelines 
and treatment recommendations were also considered. Based on this information, specific recommendations were devel‑
oped on the prevention and management of physical health conditions and their risk factors amongst people with SMD.
Results: Nineteen recommendations were made in relation to the seven key priority physical health conditions and 
risk factors, alongside best practice statements for each condition. A mixture of conditional and strong recommen‑
dations were made, the quality of evidence underpinning these was generally low or very low. This is owing to the 
dearth of direct evidence relating to people living with SMD and comorbidities.
Conclusions: This paper presents evidence‑based recommendations to prevent and manage physical health condi‑
tions in people with SMD. The recommendations are designed to inform policy makers, healthcare providers as well 
as other stakeholders about what they can do to improve the management of physical health conditions in adults 
with SMD and support the promotion of individual health behaviors to reduce the risk factors for these conditions. If 
implemented, these recommendations can improve the care that people with SMD receive for their physical health 
conditions in an equitable and person‑centered manner, so that in future in relation to premature mortality ‘no‑one is 
left behind’.
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Background
The global burden of disease associated with mental dis-
orders and addictive disorders was reported to be 7% as 
measured in disability-adjusted life-years (DALYs) in 
2016 [1], with severe mental disorders (SMD) (i.e. schiz-
ophrenia and related conditions, bipolar disorder and 
moderate to severe depression) specifically affecting over 
Page 2 of 10Gronholm et al. Int J Ment Health Syst           (2021) 15:22 
4% of the adult population worldwide [2]. This impact 
may also be underestimated due to the challenges in 
measuring the burden of mental disorders, and mental 
disorders may actually be level with cardiovascular and 
circulatory diseases in terms of DALYs, that is, account-
ing for 13% of DALYs [3].
In addition to causing a large proportion of morbid-
ity, mental disorders—especially SMD—are linked with 
poorer health outcomes and increased mortality.
People with SMD have a 2–3 times higher average 
mortality compared to the general population, reflecting 
a 10–20 year reduction in life expectancy [4–6]. This pat-
tern of increased rates of mortality is observed in both 
high and low-income settings [7–11].
While some of this excess mortality among people with 
SMD is attributed to unnatural causes (accidents, homi-
cide, or suicide), the majority of deaths amongst people 
with SMD are attributable to physical health conditions, 
both non-communicable (NCDs) and communicable [4]. 
People with SMD have approximately 1.5–3 times higher 
risk of cardiovascular morbidity and mortality when 
compared with the general population [12]. People with 
SMD also have higher rates of diabetes mellitus [13], with 
reports of a 2–threefold higher prevalence compared 
with the general population. Infectious diseases such as 
HIV/AIDS contribute further to the high rates of prema-
ture death amongst people with SMD, as do other infec-
tious diseases such as tuberculosis and hepatitis B and C 
[14].
There are a number of contributing factors that 
increase the risk of non-communicable diseases (such 
as cardiovascular disease, diabetes, respiratory illnesses, 
and cancers) for people with SMD. Firstly, adverse health-
related behaviors such as physical inactivity, unhealthy 
diets, tobacco consumption, and alcohol use are more 
prevalent in people with SMD [15, 16]. Additionally, iat-
rogenic effects of many psychotropic medications used to 
treat the symptoms of SMD are also associated with an 
increased risk of developing physical health conditions 
and associated complications [12, 17]. Moreover, a grow-
ing body of research is illuminating the pathophysiologi-
cal links between brain and body illness, via the stress 
cascade. Chronic stress can lead to blunted hypotha-
lamic–pituitary–adrenal axis activity and inflammatory 
dysregulation throughout the body, which is associated 
with the development of both mental and physical ill-
nesses [18, 19]. One well-known example is the impact 
of chronic stress on cardiovascular disease and the inci-
dence of cardiovascular events [20, 21].
Overall, equitable access to comprehensive health ser-
vices remains out of reach for the majority of people with 
SMD. People with SMD often lack access to health ser-
vices or receive poor quality care, including promotion 
and prevention, screening, and treatment [22]. Socio-
economic disadvantages and stigma and discrimination 
associated with SMD may further influence the health 
and health care amongst this population [23]. Most stud-
ies reporting on excess mortality in people with SMD are 
from high income countries. The situation may be worse 
in low-income settings where resources are inadequate, 
institutions are not well managed and access to quality 
mental health care and physical care is limited [6, 11].
It is crucial to address the disparities in health care 
access and provision for people with SMD, and develop 
comprehensive evidence-based clinical guidelines that 
provide recommendations to support the scale-up of 
care for physical health conditions and their risk factors 
affecting people living with SMD globally.
This paper is based on the WHO Guidelines on Man-
agement of Physical Health Conditions in Adults with 
Severe Mental Disorders (PH-SMD) [24], and presents 
recommendations to health care workers at all levels of 
the health care system, and other stakeholders, on how 
to prevent and manage comorbid physical and mental 
health conditions.
Methodology for the development of guidelines
These global evidence-informed recommendations were 
developed by WHO, following a rigorous guideline devel-
opment methodology [25] and the GRADE (Grading of 
Recommendations Assessment, Development and Evalu-
ation) approach [26, 27].
The process started with an initial phase to identify the 
key conditions and associated risk factors that would be 
included in the guidelines. A scoping review was con-
ducted of conditions and risk factors that increase the 
morbidity and mortality for people with SMD. This scop-
ing review involved three stages: (i) an initial broad focus 
on risk factors interventions for excess mortality and 
morbidity in people with SMD, guided by previous work 
exploring epidemiology and risk factors for excess mor-
tality in persons with SMD [28] and the physical health 
conditions and risk factors identified in this report; (ii) 
review of existing WHO guidelines, and (iii) findings of 
a WHO consultation on the topic, and other relevant 
WHO documents and discussions with the WHO steer-
ing group. The scoping review results were considered in 
a consultation with the Guideline Development Group 
(GDG), reflecting externally appointed international 
experts convened by the WHO. Following this review 
and consultation, seven key priority health conditions 
and risk factors were identified: tobacco use disorder, 
overweight/obesity, substance use disorder, cardiovas-
cular disease and cardiovascular risk, diabetes mellitus, 
HIV/AIDS, and other infectious diseases (Tuberculosis, 
Hepatitis B/C). These conditions and risk factors are not 
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considered a comprehensive list of physical health con-
ditions, but were considered to reflect important condi-
tions shown to increased morbidity and mortality for 
people with SMD, and for which there was evidence 
available.
A priori research questions were formulated for these 
conditions and risk factors, following the PICO format 
(Population, Intervention, Comparison group, Out-
comes). These questions were ratified by the WHO 
Guideline Review Committee, to define the final specific 
research questions regarding the physical health condi-
tions and risk factors that would be addressed in the final 
disseminated guidelines. These specific PICO questions 
were addressed through comprehensive searches of sys-
tematic review evidence. High quality systematic reviews 
were identified through the Cochrane Library (including 
DARE), PubMed/Medline, Embase, Psycinfo, Epistemon-
ikos, and the Global Health Library; the searches for each 
question were formulated informed by consultations 
with guideline methodologists and subject experts at the 
WHO.
Following these searches, n = 23 systematic reviews 
(selected from well over n = 150 reviews) were identified 
that met the criteria of: (i) recency (published within the 
previous 5 years [i.e. 2013 onwards]); (ii) methodological 
quality (sufficiently high ratings [positive rating on more 
than 6 of 11 quality domains] on the Assessment of Mul-
tiple Systematic Reviews tool (AMSTAR) [29–31]); and 
(iii) relevance (evidence in reviews was closely relevant to 
the PICO population).
To ensure evidence-based recommendations for 
the guidelines were developed in a rigorous manner, 
the evidence identified through these searches was 
reviewed using the GRADE methodology [26, 27] by 
two independent raters. Information relevant to the 
PICO questions for each key condition and risk factor 
were extracted. In line with WHO principles for guide-
line development, certainty of included evidence was 
assessed via the GRADE approach, involving a quality 
assessment considering study design, risk of bias, incon-
cistencies, indirectness, imprecisions, and the reporting 
of bias in included studies. Based on this GRADE assess-
ment, quality of the evidence was characterised as either 
high, moderate, low or very low.
Where relevant systematic review evidence could not 
be identified for a given condition or risk factor, other 
related guidelines and tools/resources were considered 
in the development of the recommendations. Some of 
these are detailed in Box 1. When these resources were 
considered, the process adopted to review the evidence 
entailed the following steps: (i) review of evidence that 
exists for the interventions to manage physical health 
conditions and associated risk factors in people with 
SMD; (ii) examination of the extent to which existing 
recommendations for the general population (especially 
from existing WHO guidelines) can be applied to people 
with SMD; (iii) examination of when and how these rec-
ommendations need to be adapted for people with SMD; 
and, (iv) to provide recommendations that are specific to 
this population when needed.
Final recommendations were developed via discussions 
with the GDG, guideline methodologists, the evidence 
review team, and the WHO secretariat. These discus-
sions considered the background evidence for each PICO 
question; the GRADE evidence profiles and certainty 
of evidence; and specific aspects of the conditions and 
risk factors specified in the PICO questions (e.g. prior-
ity, anticipated effects, value attached to outcomes, cost 
effectiveness, impact on health equity, acceptability, and 
feasibility). The final recommendations that emerged 
from this report on both the certainty of evidence and 
the strenght of the recommendation.
The GRADE evidence tables and Evidence to Deci-
sion tables based on which recommendations are made 
are available in the guideline Evidence Profile document, 
available at the WHO website [32].
Box 1: Related WHO guidelines and tools
1. Mental Health Gap Action Programme (mhGAP) 
Intervention Guide for mental, neurological, and sub-
stance use disorders in non-specialized health settings 
(Version 2.0). Geneva, WHO, 2016. http://www.who.
int/menta l_healt h/mhgap /mhGAP _inter venti on_
guide _02/en/
2. Package of Essential Noncommunicable (PEN) 
Disease Interventions for Primary Health Care in 
Low-Resource Settings. Geneva, WHO, 2010. http://
www.who.int/cardi ovasc ular_disea ses/publi catio ns/
pen20 10/en/
3. Strengthening health systems for treating tobacco 
dependence in primary care. Building capacity for 
tobacco control: training package. http://www.who.
int/tobac co/publi catio ns/build ing_capac ity/train ing_
packa ge/treat ingto bacco depen dence /en/
4. Global recommendations on physical activity for 
health. Geneva, WHO, 2010. http://www.who.int/
dietp hysic alact ivity /publi catio ns/97892 41599 979/en/
5. Consolidated guidelines on HIV prevention, 
diagnosis, treatment, and care for key populations. 
Geneva, WHO, 2016 update. http:// www.who.int/hiv/
pub/guide lines /keypo pulat ions-2016/en/
6. Consolidated guidelines on the use of antiret-
roviral drugs for treating and preventing HIV infec-
tion. Recommendations for a public health approach. 
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Second edition. Geneva, WHO, 2016. http://www.
who.int/hiv/pub/arv/arv-2016/en/
7. WHO guidelines for the treatment of drug-sus-
ceptible tuberculosis and patient care (2017 update) 
https ://www.who.int/tb/publi catio ns/2017/dstb_guida 
nce_2017/en/
8. WHO consolidated guidelines on drug-resistant 
tuberculosis treatment https ://www.who.int/tb/publi 
catio ns/2019/conso lidat ed-guide lines -drug-resis tant-
TB-treat ment/en/
9. Guidelines for the prevention, care, and treatment 
of persons with chronic hepatitis B infection. Geneva, 
WHO, 2015. https ://www.who.int/hepat itis/publi catio 
ns/hepat itis-b-guide lines /en/
10. Guidelines for the screening, care, and treatment 
of persons with chronic hepatitis C infection. Geneva, 
WHO, 2016. http://www.who.int/hepat itis/publi catio 
ns/hepat itis-c-guide lines -2016/en/
Results
WHO recommendations: management of physical health 
conditions in adults with severe mental disorders
The primary audience for the WHO Guidelines on Man-
agement of Physical Health Conditions in Adults with 
SMD (PH-SMD) is health care workers providing services 
for people with SMD at all levels of the health care sys-
tem, including outpatient and inpatient care at first-level, 
second-level, district and tertiary healthcare facilities. In 
addition, these guidelines are of interest to policy makers 
and health care planners at the national and local levels, 
national and regional mental health programme manag-
ers, national and regional primary care programme man-
agers, members of national and local health departments, 
people living with SMD and their families, and groups 
representing people with SMD and their families.
Recommendations are made for the management of 
the seven physical health conditions and risk factors that 
increase the morbidity and mortality for people with SMD, 
and that were prioritized in the WHO guidelines. The 
specific recommendations made based on the evidence 
reviewed for these guidelines are presented in Box 2.
The guidelines additionally include best practice state-
ments that represent important considerations to sup-
port implementation of the recommendations.
Furthermore, information has been presented for drug-
drug interactions between medicines relevant for the 
physical health conditions and medicines used for SMD. 
Searches between both lists (medicines relevant for the 
physical health conditions and medicines used for SMD) 
were conducted using the drug-drug interaction soft-
ware Lexi-Interact [33]. Lexi-Interact was chosen as it is 
commonly used in clinical practice and scored well on 
accuracy and comprehensiveness in a recent review com-
paring five drug-drug interaction engines [34].
Box 2: WHO‑PH‑SMD Guidelines recommendations
Tobacco use disorder (in the context of tobacco cessation 
programmes)
Recommendation 1: In people with severe men-
tal disorders, combined pharmacological and non-
pharmacological interventions may be considered in 
accordance with the WHO training package (Strength-
ening health systems for treating tobacco dependence 
in primary care. Building capacity for tobacco control: 
training package). (Strength of recommendation: Con-
ditional; quality of evidence: Very low).
Recommendation 2: In people with severe mental 
disorders, a directive and supportive behavioral inter-
vention programme may be considered and should 
be tailored to the needs of the population. (Strength 
of recommendation: Conditional; quality of evidence: 
Very low).
Recommendation 3: In people with severe men-
tal disorders, varenicline, bupropion and nicotine 
replacement therapy may be considered for tobacco 
cessation. (Strength of recommendation: Conditional; 
quality of evidence: Very low).
Best practice statement: Prescribers should take into 
account potential interactions between buproprion 
and varenicline with psychotropic medications as well 
as possible contra-indications.
Overweight/obesity
Recommendation 1: Behavioral lifestyle (healthy diet, 
physical activity) interventions should be considered 
in all people with severe mental disorders who are 
overweight or obese or at risk of becoming overweight 
or obese in accordance with WHO’s Package of Essen-
tial Noncommunicable Disease Interventions (WHO 
PEN) for primary care in low-resource settings (2010). 
These interventions should be appropriate and tai-
lored to the needs of this population. (Strength of rec-
ommendation: Strong; Quality of evidence: Very low).
Recommendation 2: For people with severe men-
tal disorders who are overweight or obese, and where 
lifestyle interventions and/or switching psychotropic 
medication do not appear successful, adjunctive met-
formin may be considered. This should be consid-
ered under close clinical supervision and monitoring. 
(Strength of recommendation: Conditional; Quality of 
evidence: Low).
Best practice statements:
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• For people with severe mental disorders who are 
overweight or obese or at risk of becoming over-
weight or obese, initiating a psychotropic medica-
tion with lower propensity for weight gain should be 
considered, taking into account clinical benefits and 
potential adverse effects.
• For people with severe mental disorders who are 
overweight or obese, switching to a psychotropic 
medication with a lower propensity for weight gain 
may be considered, taking into account clinical ben-
efits and potential adverse effects.
Substance use disorders
Recommendation 1: For people with severe men-
tal disorders and comorbid substance use disor-
ders (drug and/or alcohol), interventions should be 
considered in accordance with the WHO mhGAP 
guidelines. (Strength of recommendation: Condi-
tional; Quality of the evidence: Low).
Recommendation 2: Non-pharmacological inter-
ventions (e.g. motivational interviewing) may be 
considered and tailored to the needs of people with 
severe mental disorders and substance use disor-
ders (Strength of recommendation: Conditional; 
Quality of the evidence: Very low).
Best practice statement: Prescribers should take 
into account the potential for drug-drug interac-
tions between medicines used for treatment of sub-
stance use disorders and severe mental disorders.
Cardiovascular disease and cardiovascular risk
Recommendation 1: For people with severe mental 
disorders and pre-existing cardiovascular disease, 
or with cardiovascular risk factors (e.g. high blood 
pressure or high cholesterol), pharmacological and 
non-pharmacological interventions may be con-
sidered in accordance with the WHO Package of 
Essential Noncommunicable Disease Interventions 
(WHO PEN) for primary care in low-resource set-
tings (2010) for lowering cardiovascular risk and 
management of cardiovascular disease. (Strength of 
recommendation: Strong; Quality of evidence: High 
to moderate for different interventions).
Recommendation 2: For people with severe men-
tal disorders and pre-existing cardiovascular dis-
ease, the following is recommended:
a) Behavioral lifestyle (healthy diet, physical activ-
ity) interventions may be considered. These inter-
ventions should be appropriate and tailored to the 
needs of this population. (Strength of recommenda-
tion: Conditional; Quality of evidence: Very low).
b) Collaborative care i.e. a multi-professional 
approach to patient care with a structured man-
agement plan, scheduled patient follow-up, and 
enhanced inter-professional communication, may 
be considered for cardiovascular disease manage-
ment. (Strength of recommendation: Conditional; 
Quality of evidence: Very low).
Recommendation 3: For people with severe 
mental disorders and cardiovascular risk factors, 
behavioral lifestyle (healthy diet, physical activity) 
interventions may be considered. These interven-
tions should be appropriate and tailored to the 
needs of this population. (Strength of recommen-
dation: Conditional; Quality of evidence: Very 
low).
Best practice statements: For people with severe 
mental disorders and pre-existing cardiovascular 
disease:
• Initiating a psychotropic medication with lower 
propensity for cardiovascular risk is a strategy that 
should be considered, taking into account clinical 
benefits and potential adverse effects.
• Switching to a psychotropic medication with 
lower propensity for cardiovascular risk may be 
considered, taking into account clinical benefits 
and potential adverse effects.
• For people with severe mental disorders and pre-
existing cardiovascular disease or cardiovascular 
risk factors:
• Prescribers should be aware of potential inter-
actions between prescribed medicines for car-
diovascular disease and prescribed psychotropic 
medications, which may affect cardiovascular risk. 
Cardiovascular outcomes and risk factors should 
be monitored and dose adjustment of cardiovascu-
lar medicines may be required.
Diabetes mellitus
Recommendation 1: For people with severe 
mental disorders and diabetes mellitus, inter-
ventions in accordance with the WHO Package 
of Essential Non-communicable (PEN) Disease 
Interventions for Primary Health Care in Low-
Resource Settings should be considered for dia-
betes management.(Strength of recommendation: 
Strong; Quality of evidence: Low).
Recommendation 2: Behavioral lifestyle inter-
ventions should be considered for all people with 
severe mental disorders and diabetes mellitus. 
These interventions should be appropriate and 
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tailored to the needs of this population. (Strength 
of recommendation: Strong; Quality of evidence: 
Very low).
Recommendation 3: In people with depression 
and comorbid diabetes mellitus, cognitive behav-
ior therapy for treatment of depression may be 
considered. (Strength of recommendation: Condi-
tional; Quality of evidence: Very low).
Best Practice Statements: For people with 
severe mental disorders and diabetes mellitus:
• Initiating an anti-psychotic medication with lower 
propensity for producing hyperglycaemia should be 
considered, taking into account clinical benefits and 
potential adverse effects.
• Switching to an anti-psychotic medication with 
lower propensity for producing hyperglycaemia is a 
strategy that may be considered, taking into account 
clinical benefits and potential adverse effects.
• Prescribers should be aware of potential interactions 
between prescribed medicines for diabetes mellitus 
and prescribed psychotropic medicines, which may 
affect glycaemic control. Glycaemic control should 
be monitored and dose adjustment of medicines 
may be required.
HIV/AIDS
Recommendation 1: For people with severe men-
tal disorders and HIV/ AIDS, antiretroviral drugs 
should be considered in accordance with the WHO 
Updated recommendations on first-line and sec-
ond-line antiretroviral regimens. (Strength of the 
recommendation: Strong; Quality of the evidence: 
Moderate).
Recommendation 2: Additional psychosocial 
support for treatment adherence should be pro-
vided to people with HIV and severe mental dis-
orders in accordance with the WHO consolidated 
guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection. (Strength 
of the recommendation: Strong; Quality of the evi-
dence: Moderate).
Best practice statement: for people with severe 
mental disorders and HIV/ AIDS, prescribers 
should take into account the potential for drug-
drug interactions between antiretroviral drugs and 
psychotropic medicines.
Other infectious diseases (Tuberculosis, Hepatitis B/C)
Recommendation 1: For people with severe mental 
disorders and TB, pharmacological management 
should be considered in accordance with the WHO 
guidelines for the treatment of drug-susceptible 
tuberculosis and patient care and the WHO treat-
ment guidelines for drug-resistant tuberculosis. 
(Strength of the recommendation: Strong; Quality of 
the evidence: Low).
Recommendation 2: For people with severe men-
tal disorders and TB, non-pharmacological (social, 
psychological) management should be consid-
ered in accordance with the WHO guidelines for 
the treatment of drug-susceptible tuberculosis and 
patient care and the WHO treatment guidelines for 
drug-resistant tuberculosis. (Strength of the recom-
mendation: Strong; Quality of the evidence: Low).
Recommendation 3: For people with severe 
mental disorders and Hepatitis B, treatment 
should be considered in accordance with the 
WHO guidelines for the prevention, care and 
treatment of persons with chronic Hepatitis B 
infection. (Strength of the recommendation: 
Strong; Quality of the evidence: Low).
Recommendation 4: For people with severe 
mental disorders and Hepatitis C, treatment 
should be considered in accordance with the 
WHO guidelines for the screening care and treat-
ment of persons with chronic Hepatitis C infection. 
(Strength of the recommendation: Strong; Quality 
of the evidence: Low).
Best practice statement: For people with severe 
mental disorders and TB and/or Hepatitis B/, pre-
scribers should take into account the potential for 
drug-drug interactions between TB medicines, 




The recommendations in the WHO guidelines must be 
implemented using a person-centered and integrated 
approach to address factors associated with increased 
morbidity and mortality in people with SMD. This inte-
gration is needed at four levels: screening and early 
detection of physical health conditions, counselling for 
behavioral risk factors, assessment and management of 
cardiovascular disease risk, and management of estab-
lished physical and mental health conditions.
We propose a multilevel intervention framework that 
will be useful for designing, implementing and evalu-
ating interventions and programmes to reduce excess 
mortality in people with SMD [4]. The first level is 
individual-focused interventions. The second and third 
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levels of the framework consist of strategies focused on 
the health systems and socio-environmental context, 
respectively, which provide the enabling environment 
for implementation of the recommendations.
1. The individual-focused interventions include an ena-
bling environment to follow the recommendations 
with support to programme managers and health 
care practitioners in the use of evidence-based prac-
tices.
2. The next level in the framework encompasses strate-
gies within health systems to strengthen them such 
as care coordination and increased workforce.
3. The broadest level of the framework incorporates 
socioenvironmental factors and includes community 
interventions such as peer and family support pro-
grammes and stigma reduction programs as well as 
policy-level interventions that ensure parity for men-
tal health.
Limitations of the guideline development process
The strength of these guidelines lies in the transparent 
and robust methodologies that were applied for evidence 
synthesis, and the development of recommendations 
according to the WHO Handbook for Guideline Devel-
opment [25, 35]. However, these guidelines have some 
limitations.
Developing recommendations for physical health con-
ditions and associated risk factors in people with SMD 
within the formal WHO guideline development frame-
work highlighted several challenges, arising mainly from 
the extent of the available evidence. Much of the evidence 
came from well-resourced settings which could poten-
tially impact on generalizability. For example, malnutri-
tion in SMD was anecdotally highlighted as a concern in 
some low- and middle-income settings (as opposed to 
obesity), yet no studies meeting inclusion criteria were 
identified on this important issue.
One of the most challenging aspects of the process was 
generalizing evidence developed for the general popu-
lation to people with SMD. While general population 
interventions geared towards NCDs, infectious diseases 
or other health problems are likely to be as effective for 
persons with SMD, given the special needs of this pop-
ulation, interventions for SMD may require tailoring. 
However, the evidence for this was limited. In instances 
where the evidence was limited, we took advantage of the 
GRADE methodology [26, 27], which clearly recognizes 
that, in addition to the evidence base, other aspects that 
are expected to inform the recommendations include 
consideration of values such as gender equality, equity 
and the protection of human rights, feasibility, resource 
use and the knowledge and experience of the Guideline 
Development Group experts.
Another limitation of these guidelines is that, given 
feasibility constraints, they are based on evidence from 
existing systematic reviews. Although these reflect the 
most recent evidence, this approach may have led to 
omission of more recent individual studies not included 
in these reviews. Also, people with SMD may have more 
than one physical health condition or risk factor. How-
ever, the available evidence for these guidelines is only 
focused on individual health conditions. This means 
these guidelines do not examine multiple co-morbidi-
ties, albeit tackling multimorbidity is recognized as a key 
global health challenge [36].
Since the publication of these guidelines, the SARS-
CoV-2 (COVID-19) pandemic represents a further con-
dition which warrants particular attention in relation to 
people with SMD [37, 38]. It seems likely that COVID-19 
will exacerbate risk factors for excess mortality amongst 
this population, albeit the extent of this impact is not 
yet clear. Measures are called for to safeguard the physi-
cal health of people with SMD specifically during the 
COVID-19 pandemic, for example through individual 
support with infection prevention alongside health pro-
motion strategies such as the ones presented in these PH-
SMD guidelines, and continued access to contact with 
mental healthcare teams and reviews of mental health 
needs [39]. Future research and knowledge gaps.
The guideline development process highlighted a rela-
tive dearth of evidence relating to people living with 
SMD and comorbidities. While evidence from the gen-
eral population on comorbidities may be tailored to SMD 
populations, there is potentially a need for specific inter-
ventions that have been developed with SMD popula-
tions in mind. Another important area of research will be 
to assess the effects of health system and policy interven-
tions on excess mortality in SMD. We need to understand 
why those with SMD have not benefitted from trends in 
the general population towards reduced mortality in cer-
tain diseases and smoking cessation. Researchers should 
take advantage of natural experiments, and design stud-
ies in health systems and at the population level to evalu-
ate the impact of these programs.
Many people with SMD have multiple cardiovascu-
lar and other risk behaviors which may be modifiable, 
and future research should test interventions addressing 
multiple risk factors, as well as those which are directly 
linked to mortality.
Cost-effectiveness models of different approaches 
in people with SMD are important, especially in low 
resource settings, however there was very little evidence 
identified relating to this important issue. Future research 
in this area will be important as we aim to achieve 
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universal health coverage and to address the physical 
health needs of this vulnerable population.
Research is needed to identify and manage barriers to 
and facilitators of implementing evidence-based guid-
ance and policy recommendations. We need to under-
stand how to deliver evidence-based interventions 
successfully in the real world, taking into account train-
ing and workforce issues, and the often-limited resources 
in local community settings. We need to understand to 
what extent interventions and programs could or should 
be disseminated across countries.
Finally, to gain a better understanding of the different 
perspectives involved, qualitative research is needed to 
understand the experiences of users, providers, family 
members, as well as professionals’ receptivity to educa-
tion and training.
Conclusions
In this paper we present evidence-based recommen-
dations to manage physical health conditions and 
associated risk factors in people with SMD. The rec-
ommendations are designed to inform policy makers, 
healthcare providers as well as other stakeholders about 
what they can do to improve the management of physi-
cal health conditions in adults with SMD and support 
the promotion of individual health behaviors to reduce 
the risk factors for these conditions.
By decreasing morbidity and premature mortality 
amongst people with SMD, these guidelines will help 
achieve target 3.4 of the United Nations Sustainable 
Development Goals (“By 2030, reduce by one third 
premature mortality from non-communicable diseases 
through prevention and treatment and promote men-
tal health and well-being”) [40] and facilitate the imple-
mentation of WHO’s Comprehensive Mental Health 
Action Plan [41].
These guidelines will be reviewed in three to five 
years, unless an earlier review and update is warranted 
by breakthrough research. New evidence in these 
areas is regularly monitored by WHO, in consultation 
with international experts and academic partners. We 
also expect revisions to include a review of relevant 
new questions or areas currently not covered by these 
guidelines.
We intend that the publication of the WHO guidelines, 
and the evidence-base that underpins them, will stimu-
late interest in the global scientific, policy and practi-
tioner communities in strengthening evidence where it 
is weak. We also hope that the guidelines will improve 
the care that people with SMD receive for their physical 
health conditions in an equitable and person-centered 
manner, so that in future in relation to premature mortal-
ity ‘no-one is left behind’.
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